Nephropathy-Pipeline Review, H1 2015

Nephropathy-Pipeline Review, H1 2015

  • Products Id :- GMDHC6729IDB
  • |
  • Pages: 59
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Nephropathy-Pipeline Review, H1 2015


Global Markets Direct's, 'Nephropathy-Pipeline Review, H1 2015', provides an overview of the Nephropathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nephropathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Nephropathy

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Nephropathy and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Nephropathy pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Nephropathy

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Nephropathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Nephropathy Overview 6

Therapeutics Development 7

Pipeline Products for Nephropathy-Overview 7

Pipeline Products for Nephropathy-Comparative Analysis 8

Nephropathy-Therapeutics under Development by Companies 9

Nephropathy-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Nephropathy-Products under Development by Companies 13

Nephropathy-Companies Involved in Therapeutics Development 14

Anthera Pharmaceuticals Inc. 14

Boehringer Ingelheim GmbH 15

ChemoCentryx, Inc. 16

Ischemix 17

Promedior, Inc. 18

Nephropathy-Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

blisibimod-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

CCX-168-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

CMX-2043-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

imatinib mesylate-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

PRM-151-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

R-801-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

R-901-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Small Molecule to Inhibit Casein Kinase 2 for Cancer and Nephritis-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Nephropathy-Recent Pipeline Updates 44

Nephropathy-Dormant Projects 53

Nephropathy-Discontinued Products 54

Nephropathy-Product Development Milestones 55

Featured News & Press Releases 55

Mar 16, 2015: Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for IgA Nephropathy 55

Oct 01, 2014: Anthera Pharmaceuticals Announces Update On Strategic Partnership Discussions For Blisibimod 55

Sep 25, 2013: Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting 55

Jun 24, 2013: Anthera Pharma Initiates BRIGHT-SC Phase II Clinical Study In IgA Nephropathy With Blisibimod 56

Appendix 58

Methodology 58

Coverage 58

Secondary Research 58

Primary Research 58

Expert Panel Validation 58

Contact Us 58

Disclaimer 59

List of Tables

Number of Products under Development for Nephropathy, H1 2015 7

Number of Products under Development for Nephropathy-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Late Stage Development, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Comparative Analysis by Early Stage Development, H1 2015 12

Products under Development by Companies, H1 2015 13

Nephropathy-Pipeline by Anthera Pharmaceuticals Inc., H1 2015 14

Nephropathy-Pipeline by Boehringer Ingelheim GmbH, H1 2015 15

Nephropathy-Pipeline by ChemoCentryx, Inc., H1 2015 16

Nephropathy-Pipeline by Ischemix, H1 2015 17

Nephropathy-Pipeline by Promedior, Inc., H1 2015 18

Assessment by Monotherapy Products, H1 2015 19

Number of Products by Stage and Target, H1 2015 21

Number of Products by Stage and Mechanism of Action, H1 2015 23

Number of Products by Stage and Route of Administration, H1 2015 25

Number of Products by Stage and Molecule Type, H1 2015 27

Nephropathy Therapeutics-Recent Pipeline Updates, H1 2015 44

Nephropathy-Dormant Projects, H1 2015 53

Nephropathy-Discontinued Products, H1 2015 54

List of Figures

Number of Products under Development for Nephropathy, H1 2015 7

Number of Products under Development for Nephropathy-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Early Stage Products, H1 2015 12

Assessment by Monotherapy Products, H1 2015 19

Number of Products by Top 10 Targets, H1 2015 20

Number of Products by Stage and Top 10 Targets, H1 2015 21

Number of Products by Top 10 Mechanism of Actions, H1 2015 22

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 23

Number of Products by Top 10 Routes of Administration, H1 2015 24

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 25

Number of Products by Top 10 Molecule Types, H1 2015 26

Number of Products by Stage and Top 10 Molecule Types, H1 2015 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Anthera Pharmaceuticals Inc.

Boehringer Ingelheim GmbH

ChemoCentryx, Inc.


Promedior, Inc.

Nephropathy Therapeutic Products under Development, Key Players in Nephropathy Therapeutics, Nephropathy Pipeline Overview, Nephropathy Pipeline, Nephropathy Pipeline Assessment

select a license

Single User License
USD 2000 INR 135980
Site License
USD 4000 INR 271960
Corporate User License
USD 6000 INR 407940



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]